Cancer Research UK Tests Therapy for Advanced Ovarian, Other Cancers in Phase 1 Trial

Cancer Research UK Tests Therapy for Advanced Ovarian, Other Cancers in Phase 1 Trial
An investigational therapy called LY3143921 hydrate will be tested for the first time in a large Phase 1 clinical trial for patients with advanced cancers, including ovarian cancer. The trial (NCT03096054) will be conducted at four centers in the United Kingdom under the supervision of the Cancer Research UK (CRUK) Centre for Drug Development (CDD). In preclinical studies with mice, LY3143921 hydrate showed potential in cancer by selectively inhibiting the Cdc7 protein, which helps cells divide correctly. Cancer cells divide more rapidly than normal cells, forcing them to depend greatly on Cdc7. This makes them more susceptible to drugs that inhibit the protein's activity. Now, Eli Lilly's drug candidate will be tested in cancer patients for the first time. In the first phase of the study, researchers will assess the drug’s safety and efficacy in several cancers, including advanced bowel, lung, ovarian, urothelial (those that can affect bladder, ureters, and renal pelvis), pancreatic, breast, head and neck, and esophageal cancer. Increasing doses of LY3143921 hydrate will be administered to patients so that researchers can determine the dose that most effectively targets cancer cells without causing harm. In the trial’s second part, large groups of patients will receive the most effective dose of the drug and researchers will investigate the therapy's mode of action. The drug will be delivered once daily over 21 days. The treatment will be repeated up to 12 times, but if a patient is benefiting, they may continue to receive
Subscribe or to access all post and page content.